A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...

By hoodwinking seniors into private Medicare Advantage plans, insurers profit by denying care and bankrupting hospitals.

In an interview, Scholar Rock's chief medical officer talks about benefits seen in clinical trials of its muscle-targeted SMA therapy.

However, its presence is steadily dropping, according to local drug-checking program data. The Philadelphia Department of Public Health says medetomidine has emerged as a primary adulterant and is now ...

Childhood-onset striatonigral neurodegeneration robs children of the ability to walk and talk by age five. Researchers at ...

Anecdotal reports suggest drugs like Ozempic may curb not just appetite but also impulsive or addictive behaviour, hinting at ...

Nearly 50% of MS patients report pronounced fatigue, which has a significantly negative impact on their well-being, a Finnish ...

Since dry skin needs a good moisturizer every day, you should be using a product you really love — that’s why we tested 8 top ...

The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, ...

Wasatch Global Select Fund—Investor Class was down -3.90%, underperforming the benchmark MSCI AC (All Country) World Index, ...

NEW YORK, NY / ACCESS Newswire / March 24, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ:ICLR) between July 27, 2023 and ...

We recently published a list of the 12 Best Diagnostics Stocks to Invest In Right Now. In this article, we are going to take ...